- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03189381
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
A Pilot Phase 2 Study Evaluating Dose De-escalation in Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain acceptable in-brain distant control. The WBRT dose would decrease as the study moves forward, both in terms of absolute value and equivalent dose in 2 Gray fractions (EQD2) (as determined by the linear quadratic radiobiological model). The absolute value of the simultaneous integrated boost (SIB) dose will change with each dose level because the number of fractions delivered will depend on the WBRT dose. As such, the SIB dose will be manipulated such that the EQD2 will remain essentially equivalent despite the difference in the number of fractions delivered. This design will ensure that the only variable is the change in WBRT dose.
The concept is that WBRT with SIB would be expected to maximize both local and in-brain distant control as has already been shown in studies exploring WBRT with SRS boost. However, by itself WBRT with SIB does not address the concern over neurocognitive outcomes. Therefore, investigators hypothesize that there is a lower WBRT dose threshold that will maintain acceptable in-brain distant control, particularly in the setting of a SIB to gross lesions to maintain treated lesion control. In addition, lower overall brain dose (including lower hippocampal dose without specific hippocampal avoidance) may potentially improve neurocognitive function. Investigators are also interested in evaluating treated lesion control, overall survival, neurocognitive sequelae of therapy, quality of life, performance status, and adverse effects of therapy. Biomarker identification for potential correlative circulating tumor DNA and microRNA is an exploratory endpoint to generate data for future prospective evaluation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective Evaluate two de-escalated whole brain radiation dose levels (in the setting of simultaneous integrated boost to gross lesions) with respect to in-brain distant control for brain metastases, defined as an in-brain failure rate outside of the planning target volume at 6 months of < 20%.
Secondary Objectives
- Evaluate treated lesion control at 6 months for brain metastases in the setting of a predetermined total biologically effective SIB dose as determined by radiographic progression within the planning target volume with fusion and overlay of follow-up MRIs.
- Evaluate overall survival at 6 months for brain metastases in the setting of WBRT with SIB.
- Evaluate changes in neurocognitive function after WBRT with SIB in the following domains: verbal learning and memory as assessed by the Hopkins Verbal Learning Test - Revised (HVLT-R).
- Evaluate changes in health-related quality of life as assessed by the Functional Assessment of Cancer Therapy with Brain Subscale (FACT-Br) after WBRT-SIB for brain metastases.
- Evaluate changes in performance status as assessed by the Karnofsky Performance Status tool after WBRT-SIB for brain metastases.
- Evaluate adverse events after WBRT-SIB for brain metastases according to current CTCAE criteria.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Methodist Hospital
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age ≥ 18 at time of consent.
- Ability to provide written informed consent and HIPAA authorization.
- Pathological diagnosis of any solid tumor histology (from any site in the body).
- Pathological or clinical (i.e., by imaging) diagnosis of brain metastatic tumor lesions.
- Total volume of lesions ≤ 30 cm3.
Maximum volume of largest lesion ≤ 5 cm3.
a. This volume limit would be equivalent to a largest diameter of about 2.1 cm, assuming a perfect sphere.
- Not a candidate for or eligible for but refused Gamma Knife radiosurgery.
Exclusion Criteria
- Previous radiation to the brain, including WBRT or brain radiosurgery.
- Life expectancy < 6 months (as estimated per current ds-GPA).
- For histologies not included in the ds-GPA publications or otherwise noted online at brainmetgpa.com, the PI will use either published or validated data, or the PI's best clinical judgment to determine the patient's expected survival.
- Inability to comply with treatment per investigator discretion.
- Inability to complete neurocognitive assessments per investigator discretion.
Of note, tumor lesion number is not an inclusion or exclusion criteria as we are using volume-based criteria instead.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Standard PCI dose
|
Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
|
Experimental: Cohort B
Low PCI dose
|
Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0
Gy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-brain distant failure rate
Time Frame: 6 months
|
An actuarial 6-month rate of new parenchymal lesions seen outside the planning target volume of any lesion that received SIB on any post-treatment MRI (in all 3 planes)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treated lesion control
Time Frame: 6 months
|
An actuarial 6-month rate of any new, recurrent, or progressing (as defined by Response Assessment in Neuro-Oncology Brain Metastases criteria) tumor within the planning target volume on any post-treatment MRI
|
6 months
|
Overall survival
Time Frame: 6 months
|
An actuarial 6-month rate of patients still alive regardless of disease status
|
6 months
|
Change in neurocognitive function
Time Frame: 6 months
|
Total change in score of neurocognitive tests (Hopkins Verbal Learning Test - Revised, Groton Maze, and Two or One Back Test)
|
6 months
|
Change in health-related quality of life
Time Frame: 6 months
|
Total change in score of health-related quality of life test (Functional Assessment of Cancer Therapy with Brain Subscale)
|
6 months
|
Change in performance status
Time Frame: 6 months
|
Total change in performance status score (Karnofsky)
|
6 months
|
Incidence of early and late adverse effects
Time Frame: 1 year
|
Adverse effects will be defined per CTCAE
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin R. Shiue, MD, Indiana University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IUSCC-0605
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Istituto Clinico HumanitasRecruitingBrain Metastases, AdultItaly
-
Mustafa Khasraw, MBChB, MD, FRCP, FRACPDaiichi SankyoNot yet recruitingA Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer)Brain Metastases, AdultUnited States
-
Istituto Clinico HumanitasBrainlabRecruitingBrain Metastases, AdultItaly
-
Universitaire Ziekenhuizen KU LeuvenRecruitingBrain Metastases, AdultBelgium
-
University Hospital, GrenobleNH TherAguix SASRecruitingRadiotherapy | Brain Metastases, AdultFrance
-
Centre de recherche du Centre hospitalier universitaire...Université de SherbrookeActive, not recruitingBrain Metastases, AdultCanada
-
Juergen DebusHeidelberg UniversityCompletedBrain Metastases, AdultGermany
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
Clinical Trials on Cohort A
-
Institut du Cancer de Montpellier - Val d'AurelleNot yet recruiting
-
Regenera Pharma LtdTerminatedNonarteritic Anterior Ischemic Optic NeuropathyUnited States
-
The Methodist Hospital Research InstituteCompleted
-
Groupe Francophone des MyelodysplasiesCompleted
-
Abramson Cancer Center at Penn MedicineRecruitingAllogeneic TransplantationUnited States
-
China Academy of Chinese Medical SciencesHospital of Changchun University of Traditional Chinese MedicineUnknown
-
University Hospital, BrestRecruitingSystemic Lupus ErythematosusFrance
-
Musculoskeletal Transplant FoundationUnknownBreast ReconstructionUnited States
-
PfizerRecruitingAdolescent | Child | Child, PreschoolUnited States
-
IRCCS San RaffaeleRecruiting